2023
Neurologic Complications of Babesiosis, United States, 2011–2021 - Volume 29, Number 6—June 2023 - Emerging Infectious Diseases journal - CDC
Locke S, O’Bryan J, Zubair A, Rethana M, Moffarah A, Krause P, Farhadian S. Neurologic Complications of Babesiosis, United States, 2011–2021 - Volume 29, Number 6—June 2023 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2023, 29: 1127-1135. PMID: 37209667, PMCID: PMC10202888, DOI: 10.3201/eid2906.221890.Peer-Reviewed Original ResearchConceptsNeurologic complicationsNeurologic symptomsRisk factorsYale-New Haven HospitalInfectious Diseases journal - CDCHigh-grade parasitemiaNeurologic risk factorsRange of symptomsAdult patientsRenal failureDiabetes mellitusFrequent symptomsHospital admissionImpaired consciousnessMedical recordsEndemic areasParasitic infectionsPatientsSymptomsIntraerythrocytic protozoaComplicationsBabesiosisNew HavenDeliriumMellitus
2022
Cardiac Complications of Human Babesiosis
Spichler-Moffarah A, Ong E, O’Bryan J, Krause PJ. Cardiac Complications of Human Babesiosis. Clinical Infectious Diseases 2022, 76: e1385-e1391. PMID: 35983604, PMCID: PMC10169432, DOI: 10.1093/cid/ciac525.Peer-Reviewed Original ResearchConceptsYale-New Haven HospitalCardiac complicationsRisk factorsIntensive care unit stayCardiovascular disease risk factorsHuman babesiosisCommon cardiac complicationHigh-grade parasitemiaLife-threatening complicationsDisease risk factorsLonger median lengthQT interval prolongationHigh mortality rateUnit stayComplication groupTick-borne diseaseAdult patientsCardiac outcomesMost patientsThin blood smearsHeart failureInterval prolongationModerate illnessRecord reviewAtrial fibrillation
2020
Parasite burden and red blood cell exchange transfusion for babesiosis
O'Bryan J, Gokhale A, Hendrickson JE, Krause PJ. Parasite burden and red blood cell exchange transfusion for babesiosis. Journal Of Clinical Apheresis 2020, 36: 127-134. PMID: 33179803, PMCID: PMC9517950, DOI: 10.1002/jca.21853.Peer-Reviewed Original ResearchConceptsEnd-organ dysfunctionPeak parasitemia levelsRed blood cell exchange transfusionParasitemia levelsExchange transfusionPeak parasitemiaDisease severityParasite burdenYale-New Haven HospitalBabesia microti parasitemiaHigh-grade parasitemiaRetrospective chart reviewBabesia microti infectionNew Haven HospitalAntimicrobial agentsChart reviewHepatic dysfunctionPatient demographicsClinical statusMedian lengthLaboratory indicatorsMicroti infectionDegree of hemolysisNineteen subjectsDysfunctionClofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts
Tuvshintulga B, Vannier E, Tayebwa DS, Gantuya S, Sivakumar T, Guswanto A, Krause PJ, Yokoyama N, Igarashi I. Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts. The Journal Of Infectious Diseases 2020, 222: 1027-1036. PMID: 32310272, DOI: 10.1093/infdis/jiaa195.Peer-Reviewed Original ResearchConceptsB. microti parasitesMicroti infectionHigh-grade parasitemiaDrug-resistant tuberculosisB. microtiBabesia microti infectionAdditional preclinical studiesB. microti infectionImmunocompromised hostB. microti DNAPolymerase chain reactionPreclinical studiesIncidence of babesiosisPromising drugRadical cureMinimal doseClofazimineDay 10Blood smearsBabesia microtiNovel drugsParasitemiaChain reactionMicroscopic examinationAntimicrobial agents